English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/124080
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorCalero, Miguel-
dc.contributor.authorGómez Ramos, Alberto-
dc.contributor.authorCalero-Rueda, Olga-
dc.contributor.authorSoriano, Eduardo-
dc.contributor.authorÁvila, Jesús-
dc.contributor.authorMedina, Miguel-
dc.identifierdoi: 10.3389/fncel.2015.00138-
dc.identifierissn: 1662-5102-
dc.identifier.citationFrontiers in Cellular Neuroscience 9: 138 (2015)-
dc.description.abstractFamilial Alzheimer’s disease (AD), mostly associated with early onset, is caused by mutations in three genes (APP, PSEN1, and PSEN2) involved in the production of the amyloid βpeptide. In contrast, the molecular mechanisms that trigger the most common late onset sporadic AD remain largely unknown. With the implementation of an increasing number of case-control studies and the upcoming of large-scale genomewide association studies there is a mounting list of genetic risk factors associated with common genetic variants that have been associated with sporadic AD. Besides apolipoprotein E, that presents a strong association with the disease (OR~4), the rest of these genes have moderate or low degrees of association, with OR ranging from 0.88 to 1.23. Taking together, these genes may account only for a fraction of the attributable AD risk and therefore, rare variants and epistastic gene interactions should be taken into account in order to get the full picture of the genetic risks associated with AD. Here, we review recent whole-exome studies looking for rare variants, somatic brain mutations with a strong association to the disease, and several studies dealing with epistasis as additional mechanisms conferring genetic susceptibility to AD. Altogether, recent evidence underlines the importance of defining molecular and genetic pathways, and networks rather than the contribution of specific genes.-
dc.description.sponsorshipThis work was supported by CIBERNED, CIEN and Reina Sofia Foundations and the Carlos III Health Institute (PI12/00045).-
dc.publisherFrontiers Media-
dc.relation.isversionofPublisher's version-
dc.titleAdditional mechanisms conferring genetic susceptibility to Alzheimer’s disease-
dc.description.versionPeer Reviewed-
dc.contributor.funderFundación Centro de Investigación de Enfermedades Neurológicas-
dc.contributor.funderFundación Reina Sofía-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderCentro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España)-
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
Avila J Additional mechanisms.pdf220,83 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.